Wed, 22 Oct 2014 14:35:40 GMT
[at noodls] - 22 Oct Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox. ... This is an abstract of the ...
Wed, 22 Oct 2014 12:30:00 GMT
[Business Wire] - TapImmune, Inc. , provides an update on the status of its PolyStartTM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus.
Wed, 15 Oct 2014 16:27:26 GMT
[at noodls] - Tapimmune, a Biotech Company Focused on Stimulating the Body's Own Immune System to Fight Cancer TapImmune, a biotech company focused on stimulating the body's own immune system to fight cancer. Please ...
Tue, 23 Sep 2014 14:47:00 GMT
[Business Wire] - TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease.
Thu, 18 Sep 2014 18:30:00 GMT
Thu, 18 Sep 2014 14:30:00 GMT
Thu, 18 Sep 2014 13:00:00 GMT
[Accesswire] - SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor ...
Tue, 16 Sep 2014 12:30:00 GMT
[Business Wire] - TapImmune Inc. is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes.
Mon, 08 Sep 2014 13:05:00 GMT
[Accesswire] - Conference Being Held at Convene Times Square in Midtown NEW YORK / ACCESSWIRE / September 8, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused ...
Thu, 04 Sep 2014 13:00:00 GMT
[Accesswire] - Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (OTCQB: TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday ...
Wed, 03 Sep 2014 14:41:00 GMT
[Accesswire] - Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics ...
Tue, 26 Aug 2014 17:04:27 GMT
Tue, 19 Aug 2014 12:50:00 GMT
[Accesswire] - New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has ...
Mon, 18 Aug 2014 19:41:22 GMT
Thu, 14 Aug 2014 16:45:01 GMT
Mon, 11 Aug 2014 16:21:00 GMT
[Business Wire] - TapImmune, Inc. , , today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $
Thu, 07 Aug 2014 13:23:00 GMT
[Business Wire] - TapImmune Inc. is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN.
Thu, 24 Jul 2014 13:38:00 GMT
[Business Wire] - TapImmune Inc. , announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.
Wed, 23 Jul 2014 18:31:33 GMT
Wed, 23 Jul 2014 12:01:00 GMT
[Accesswire] - Los Angeles / ACCESSWIRE / July 23, 2014 / Last month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the companyâ€™s scientific advisory board. TapImmune, ...